Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis.

ABSTRACT:

Background & aims

We evaluated the efficacy and safety of high-dose swallowed fluticasone propionate (FP) and dose reduction in patients with eosinophilic esophagitis (EoE) and analyzed esophageal transcriptomes to identify mechanisms.

Methods

We conducted a randomized, multisite, double-blind, placebo-controlled trial of daily 1760 mcg FP in participants age 3-30 years with active EoE. Twenty-eight participants received FP, and 14 participants received placebo. After 3 months, participants given FP who were in complete remission (CR) received 880 mcg FP daily, and participants in the FP or placebo groups who were not in CR continued or started, respectively, 1760 mcg FP daily for 3 additional months. The primary end point was histologic evidence for CR. Secondary end points

SUBMITTER: Butz BK 

PROVIDER: S-EPMC4107112 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature